LEO R. ZACHARSKI, M.D.
To the editor: The judgment as to what constitutes the best treatment for patients with thrombotic thrombocytopenic purpura (TTP) is based on empiric evidence rather than on the results of controlled therapeutic trials. Unfortunately, TTP does not lend itself to such trials because of its rarity and rapidly fatal course, and because commonly accepted treatments are relatively innocuous. Attempts to evaluate the efficacy of specific forms of treatment have been frustrated because multiple treatments are usually used in individual patients, intermediate measures of responses such as changes in clinical or laboratory variables are not always a reliable guide to survival,
ZACHARSKI LR. Aspirin, Dipyridamole, and Thrombotic Thrombocytopenic Purpura. Ann Intern Med. ;96:679–681. doi: 10.7326/0003-4819-96-5-679
Download citation file:
Published: Ann Intern Med. 1982;96(5):679-681.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use